| Literature DB >> 31379891 |
Jürgen Köhl1, Rogier Kolnaar2, Willem J Ravensberg3.
Abstract
Microbial biological control agents (MBCAs) are applied to crops for biological control of plant pathogens where they act via a range of modes of action. Some MBCAs interact with plants by inducing resistance or priming plants without any direct interaction with the targeted pathogen. Other MBCAs act via nutrient competition or other mechanisms modulating the growth conditions for the pathogen. Antagonists acting through hyperparasitism and antibiosis are directly interfering with the pathogen. Such interactions are highly regulated cascades of metabolic events, often combining different modes of action. Compounds involved such as signaling compounds, enzymes and other interfering metabolites are produced in situ at low concentrations during interaction. The potential of microorganisms to produce such a compound in vitro does not necessarily correlate with their in situ antagonism. Understanding the mode of action of MBCAs is essential to achieve optimum disease control. Also understanding the mode of action is important to be able to characterize possible risks for humans or the environment and risks for resistance development against the MBCA. Preferences for certain modes of action for an envisaged application of a MBCA also have impact on the screening methods used to select new microbials. Screening of MBCAs in bioassays on plants or plant tissues has the advantage that MBCAs with multiple modes of action and their combinations potentially can be detected whereas simplified assays on nutrient media strongly bias the selection toward in vitro production of antimicrobial metabolites which may not be responsible for in situ antagonism. Risks assessments for MBCAs are relevant if they contain antimicrobial metabolites at effective concentration in the product. However, in most cases antimicrobial metabolites are produced by antagonists directly on the spot where the targeted organism is harmful. Such ubiquitous metabolites involved in natural, complex, highly regulated interactions between microbial cells and/or plants are not relevant for risk assessments. Currently, risks of microbial metabolites involved in antagonistic modes of action are often assessed similar to assessments of single molecule fungicides. The nature of the mode of action of antagonists requires a rethinking of data requirements for the registration of MBCAs.Entities:
Keywords: antagonist; biological control; mode of action; plant diseases; risk assessment; screening
Year: 2019 PMID: 31379891 PMCID: PMC6658832 DOI: 10.3389/fpls.2019.00845
Source DB: PubMed Journal: Front Plant Sci ISSN: 1664-462X Impact factor: 5.753
FIGURE 1Microbial biological control agent (MBCA) temporally interacting in situ with the targeted pathogen activating different modes of action in cascades of events.
Modes of action in relation to development and use of microbial biological control agents.
| Induced resistance | Complex bioassay on plants | Specific to broad | Low | Low | High | Knowledge transfer needed |
| Competition | Simplified bioassays | Broad | Low | High | Low | Knowledge transfer needed |
| Hyperparasitism | Simplified bioassays | Pathogen specific interactions | Low | High | Low | Knowledge transfer needed |
| Antimicrobial metabolites produced | Simplified bioassays | Specific to broad | Low | Moderate | Low | Knowledge transfer needed |
| Antimicrobial metabolites in product | Broad | Moderate | Low | Low | Similar to use of fungicides | |
| Helper strains2 | Complex bioassays | Depends on MBCA | Low | Reduced | Reduced | Knowledge transfer needed |
| Assembled consortia combining different modes of action | Broad | Low | Low | Low | Knowledge transfer needed | |
| Modulation of indigenous microbiota | Complex site-specific bioassays | Broad | Low | Medium | Low | Site-specific knowledge needed |
Modes of action in relation to risk assessment and registration of microbial biological control agents.
| Induced resistance | Very low | Very low | Very low | Very low | Low | Strain-specific | Simplification because of low intrinsic risks |
| Competition | Very low | Very low | Very low | Very low | Very low | Strain-specific | Simplification because of low intrinsic risks |
| Hyperparasitism | Very low | Very low | Very low | Very low | Very low | Strain-specific | Simplification because of low intrinsic risks |
| Antimicrobial metabolites produced | Low | Low | Low | Low | Low | Strain-specific | Simplification because of low intrinsic risks |
| Antimicrobial metabolites in product | Risk assessment relevant | Risk assessment relevant | Risk assessment relevant | Risk assessment relevant | Risk assessment relevant | Metabolite-specific | Use current regulations for PPPs |
| Helper strains1 | Low | Low | Low | Low | Low | Strain-specific | No registration required |
| Assembled consortia combining different modes of action | Low | Low | Low | Low | Low | Multiple strain-specific | New concept needed for overall risk assessments instead of risk assessment per active ingredient |
| Modulation of indigenous microbiota | Low | Low | Low | Low | Low | Microbiome characterization | No registration required |